Press Releases
05/15/2008
AVEO Pharmaceuticals to Present at the 2008 Citi Investment Research Global Health Care Conference
Read More
05/02/2008
AVEO Pharmaceuticals to Participate in Leerink Swann Solid Tumors Roundtable Conference
Read more
04/14/2008
AVEO Pharmaceuticals’ Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer; Clinical Activity and Tolerability in other Solid Tumors including Colon and Lung Cancers
Read More
04/08/2008
New Clinical Data on AVEO Pharmaceuticals’ Investigational Triple VEGFR Small Molecule Inhibitor AV-951 to be Presented at AACR Annual Meeting
Read More
03/20/2008
AVEO Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference
Read More
03/12/2008
AVEO Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
Read More
02/05/2008
AVEO Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Read More
01/31/2008
AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma
Read More
01/30/2008
AVEO Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Read More
01/03/2008
AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors
Read More
01/02/2008
AVEO Pharmaceuticals to Present at 26th Annual JPMorgan Healthcare Conference
Read More
12/04/2007
AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project
Read More
11/20/2007
AVEO Pharmaceuticals to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Read More
11/13/2007
Preclinical Data Published in Cancer Science Show AVEO's Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers
Read More
11/06/2007
Results from Phase 1 Study of AVEO’s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease
Read More
10/30/2007
AVEO Pharmaceuticals Appoints David Johnston as CFO
Read More
10/30/2007
AVEO Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Read More
10/02/2007
AVEO Pharmaceuticals to Utilize Peptech’s Breakthrough Technology to “Humanise” Internal Drug Candidates
Read More
10/02/2007
OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration
Read More
08/09/2007
AVEO Announces Successful Completion of Discovery Agreement for Novel Cancer Drugs
READ MORE
07/02/2007
AVEO featured in Boston Globe
Read more
07/02/2007
AVEO Featured in Xconomy.com
Read More
06/18/2007
AVEO PHARMACEUTICALS CEO TUAN HA-NGOC RECEIVES ERNST & YOUNG NEW ENGLAND ENTREPRENEUR OF THE YEAR® AWARD
Read more
05/03/2007
AVEO Pharmaceuticals Closes $53 Million in Series D Funding
Read more
04/25/2007
Finalists for the Ernst & Young Entrepreneur Of The Year® Award in New England Announced
Read more
04/18/2007
Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer
Read more
04/17/2007
AVEO Presents Preclinical Efficacy Data on AV-412, A Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-resistant Lung Cancer
Read more
04/12/2007
AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to be featured at AACR
Read more
04/04/2007
AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO's Novel Anti-HGF Antibody
Read more
01/04/2007
AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin
Read More
10/23/2006
AVEO Pharmaceuticals initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors
Read More
09/28/2006
AVEO and XOMA Enter Into Supply Agreement for AVEO’s Novel Anti-HGF Antibody
Read More
09/27/2006
AVEO Pharmaceuticals selected to receive 'Pharmaceutical Industry Standard of Excellence' WebAward by Web Marketing Association
Read More
04/27/2006
XOMA and AVEO Announce Agreement to Apply Human Engineering Technology™ to AV-299, AVEO's Novel Anti-HGF Antibody
Read More
04/05/2006
AVEO Pharmaceuticals Presents a Novel System for the Generation of Fully Human Breast Tumors in Mice at AACR 2006
Read More
04/04/2006
AV-412 Preclinical Efficacy Data Presented at AACR 2006
Read More
03/30/2006
Hercules Provides $15.0M Financing to AVEO Pharmaceuticals, Inc., a Biopharmaceutical Company Focused on the Discovery and Development of Novel Cancer Medicines
Read More
03/30/2006
AVEO Pharmaceuticals Appoints John Ryan, Ph.D., M.D., As Chief Medical Officer
Read More
01/05/2006
AVEO Pharmaceuticals acquires rights to novel anti-cancer compound from Mitsubishi Pharma Corporation
Read More
11/01/2005
AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Prediction
Read More
03/01/2005
GenPath Pharmaceuticals Becomes AVEO Pharmaceuticals
Read More
11/17/2003
GenPath Pharmaceuticals and Merck Enter Into Potential $100 Million Deal For The Discovery of Novel Cancer Drugs
Read More
10/29/2003
GenPath Pharmaceuticals Announces Issuance of Fundamental U.S. Patent Covering its Proprietary Cancer Models
Read More
10/01/2003
GenPath Pharmaceuticals Raises $42.7 Million in Series B Funding
Read More
» back to top
